La 11β-hydroxystéroïde déshydrogénase de type 1 – 2e partie Inhibition sélective pour traiter les anomalies métaboliques associées à l’obésité

Iovino, A.; Scheen, André

doi:10.1016/S1957-2557(09)73624-7

Article (Scientific journals)

La 11β-hydroxystéroïde déshydrogénase de type 1 – 2e partie Inhibition sélective pour traiter les anomalies métaboliques associées à l’obésité

Iovino, A.; Scheen, André

2009 • In Médecine des Maladies Métaboliques, 3 (6), p. 595-600

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/16045

DOI
10.1016/S1957-2557(09)73624-7

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

La 11-hydroxystrode dshydrognase( part 2)_ocr.pdf

Author postprint (272.99 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Obésité abdominale; diabète de type 2.; inhibition sélective; 11β-hydroxysteroïde déshydrogénase de type 1; cortisol; syndrome métabolique

Abstract :

[fr] La 11β-hydroxystéroïde déshydrogénase de type 1 (11HSD1), qui convertit la cortisone (inactive) en cortisol (actif) dans les tissus cibles, est surexprimée dans certains tissus en présence d’une obésité, surtout abdominale, et pourrait jouer un rôle dans les anomalies métaboliques associées. Des inhibiteurs non sélectifs de la 11HSD1 ont déjà été testés chez l’homme et se sont révélés peu efficaces. Le développement de nouveaux inhibiteurs, plus puissants et plus sélectifs, est en cours. Des résultats préliminaires obtenus avec divers inhibiteurs sont prometteurs, avec une diminution de l’insulinorésistance, une amélioration de la tolérance au glucose ou du contrôle glycémique et une correction de certaines anomalies liées au syndrome métabolique. Si ces résultats se confirment, les inhibiteurs sélectifs de la 11HSD1 pourraient représenter à l’avenir une nouvelle classe pharmacologique d’antidiabétiques oraux. Cet article donne au lecteur un aperçu des différentes étapes de réflexion et d’expérimentations humaines qui ont mené au développement d’inhibiteurs de la 11HSD1 à visée thérapeutique.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Iovino, A.

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

La 11β-hydroxystéroïde déshydrogénase de type 1 – 2e partie Inhibition sélective pour traiter les anomalies métaboliques associées à l’obésité

Alternative titles :

[en] 11β -hydroxysteroid dehydrogenase type 1 – Second part Selective inhibition for the management of metabolic abnormalities associated with obesity

Publication date :

December 2009

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Masson, Issy-les-Moulineaux, France

Volume :

Issue :

Pages :

595-600

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.em-consulte.com/revue/mmm

Available on ORBi :

since 01 February 2010

Statistics

Number of views

111 (2 by ULiège)

Number of downloads

409 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Iovino A, Scheen AJ. La 11β-hydroxystéroide déshydrogénase de type 1. 1e partie : Rôle de l'exposition tissulaire au cortisol dans le risque métabolique lié à l'obésité. Médecine des maladies Métaboliques, 2009;3:507-13.
Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review. The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009;94:2692-701.
Boyle CD, Kowalski TJ. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Exp Opin Ther Pat 2009;19:801-25.
Tomlinson JW, Stewart PM. Modulation of glucocorticoid action and the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007;21:607-19.
Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349:1210-3.
Basu R, Singh RJ, Basu A, et al. Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab 2005;90:3919-26.
Sandeep TC, Andrew R, Homer NZM, et al. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11â-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005;54:872-9.
Alberti L, Girola A, Gilardini L, et al. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in obese subjects. Int J Obes 2007;31:1826-31.
Paulsen SK, Pedersen SB, Fisker S, et al. 11β-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity 2007;15:1954-60.
Desbriere R, Vuaroqueaux V, Achard V, et al. 11β-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity 2006;14:794-8.
Munoz R, Carvajal C, Escalona A, et al. 11β-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients. Obes Surg 2009;19:764-70.
Tomlinson JW, Walker EA, Bujalska IJ, et al. 11β-hydroxysteroïd dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004;25:831-66.
Veilleux A, Rhéaume C, Daris M, et al. Omental adipose tissue type 1 11beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab 2009;94:3550-7.
Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009;58:46-53.
Andrew R, Westerbacka J, Wahren J, et al. The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 2005;54:1364-70.
Basu R, Basu A, Grudzien M, et al. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 2009;58:39-45.
Rask E, Olsson T, Söderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86:1418-21.
Stewart PM, Boulton A, Kumar S, et al. Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999;84:1022-7.
Rask E, Walker BR, Söderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002;87:3330-6.
Stewart PM, Tomlinson JW. Selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome, is the target liver, fat, or both? (commentary). Diabetes 2009;58:14-5.
Tomlinson JW, Finney J, Gay C, et al. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes 2008;57:2652-60.
Purnell JQ, Kahn SE, Samuels MH, et al. Enhanced cortisol production rates, free cortisol, and 11 Beta HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. Am J Physiol Endocrinol Metab 2009;296:E351-7.
Valsamakis G, Anwar A, Tomlinson JW, et al. 11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89:4755-61.
Swali A, Walker EA, Lavery GG, et al. 11beta-hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia 2008;51:2003-11.
Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985;61:536-40.
Walker BR, Andrew R. Tissue production of cortisol by 11β-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann NY Acad Sci 2006;1083:165-84.
Friedman JE, Sun Y, Ishizuka T, et al. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice. J Biol Chem 1997;272:31475 -81.
Walker BR, Connacher AA, Lindsay RM, et al. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11 oxosteroid-reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995;80:3155-9.
Andrews RC, Rooyackers O, Walker B. Effects of the 11β- hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88:285-91.
Wamil M, Seckl JR. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discov Today 2007;12:504-20.
Bujalska IJ, Gathercole LL, Tomlinson JW, et al. A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol 2008;197:297-307.
Courtney R, Stewart PM, Toh M, et al. Modulation of 11β- hydroxysteroid dehydrogenase (11βHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11βHSD1 inhibitor. J Clin Endocrinol Metab 2008;93:550-6.
Gumy C, Thurnbichler C, Aubry EM, et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 by plant extracts used as traditional antidiabetic medicines. Fitoterapia 2009; Jan 23 [Epub ahead of print].
Hawkins M, Hunter D, Kishore P, et al. INCB013739, a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. Diabetes 2008;57(Suppl.1): A99-A100 [Abstract 344-OR].
Rosenstock J, Banarer S, Fonseca V, et al. Efficacy and safety of the 11-B-HSD1 inhibitor, INCB13739, added to metformin therapy in patients with type 2 diabetes. Diabetes 2009;58(Suppl.1): LB3 [Late breaking abstract 7-LB].
Ye YL, Zhou Z, Zou HJ, et al. Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem 2009;17:5722-32.
Vantyghem MC, Marcelli-Tourvieille S, Defrance F, et al. 11β-hydroxystéroïde déshydrogénases. Avancées récentes. Ann Endocrinol (Paris) 2007;68:349-56.
Strachan MWJ, Reynolds RM, Frier BM, et al. The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes Metab 2009;11:407-14.